Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04962152
Other study ID # KMUHIRB-F(I)-20210087
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date July 7, 2021
Est. completion date May 7, 2024

Study information

Verified date July 2023
Source Kaohsiung Medical University Chung-Ho Memorial Hospital
Contact Hung-Te Hsu, MD, PhD
Phone +88673121101
Email hdhsu1228@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the postoperative analgesic effect of combined use of Naldebain® and thoracic paravertebral block in thoracoscopic surgery


Description:

Video-assisted thoracoscopic surgery (VATS) can be associated with stronger postoperative pain than is commonly believed. Pain control after thoracic surgery is important because increased acute pain has been shown to increase the incidence of chronic pain, and untreated pain may lead to increased morbidity. It is generally accepted to introduce multimodal analgesic strategies based on regional blockade, opioids and non-steroidal anti-inflammatory drugs. Paravertebral block (PVB) involves the injection of local anesthetic into a wedge-shaped space lateral to the spinal nerves as they emerge from intervertebral foramina. It produces ipsilateral somatosensory and sympathetic nerve blockade effective for anesthesia as well as for management of pain of unilateral origin from the chest and abdomen. So far, thoracic paravertebral block (TPVB) is the most common technique used for patients undergoing VATS. TPVB may be useful after VATS because a single injection of local anesthesia may provide effective analgesia for the intense short-duration pain that patients experience. Nalbuphine sebacate (NaldebainĀ®) is a long-acting prodrug of nalbuphine developed for meeting the unmet medical need of long-acting analgesics. It is a synthetic opioid agonist-antagonist analgesic of the phenanthrene series. It is chemically related to both the widely used opioid antagonist, naloxone, and the potent opioid analgesic, oxymorphone. The currently proposed clinical use of nalbuphine sebacate is a single dose of NaldebainĀ® administered intramuscularly approximately 24 h prior to the planned surgery for pain relief. The purpose of this study is to determine the safety and efficacy of TPVB combined with a single dose of intramuscular NaldebainĀ® administered preoperatively to patients scheduled to undergo VATS.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date May 7, 2024
Est. primary completion date May 7, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - 1) Subject's age: 20~65 years old - 2) American Society of Anesthesiologists (ASA) Physical Status classification: I~III - 3) Patients who need postoperative pain relief due to thoracoscopic surgery Exclusion Criteria: - 1. The patient suffers from a communication disorder - 2. The patient has coagulopathy - 3. Sick with obvious heart, lung, liver or kidney disease - 4. The patient's body mass index is less than 18.5 or greater than 35 - 5. Pregnant patients - 6. Patients who took opioids for more than three weeks before surgery - 7. Patients with contraindications to local anesthesia - 8. Patients with a history of chronic pain - 9. Patients with a history of drug allergy to Naldebain

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nalbuphine Sebacate or Sesame oil (placebo)
ultrasound-guided intramuscular injection after the induction of anesthesia immediately

Locations

Country Name City State
Taiwan Department of Anesthesiology, Kaohsiung Medical University Hospital Kaohsiung City

Sponsors (1)

Lead Sponsor Collaborator
Kaohsiung Medical University Chung-Ho Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery During the first one hour in the recovery room, the pain intensity was evaluated every 15 minutes.
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery the pain intensity was evaluated at 3 hours after surgery.
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery the pain intensity was evaluated at 6 hours after surgery.
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery the pain intensity was evaluated at 12 hours after surgery.
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery the pain intensity was evaluated at 24 hours after surgery.
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery the pain intensity was evaluated at 36 hours after surgery.
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery the pain intensity was evaluated at 48 hours after surgery.
Primary postoperative analgesic effect Use the visual analogue scale (VAS) score to assess the degree of pain after surgery the pain intensity was evaluated at 72 hours after surgery.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05534230 - Dexmedetomidine for Pain Reduction in CABG N/A
Recruiting NCT06275698 - HONEY for the Treatment of POst-Tonsillectomy Pain N/A
Recruiting NCT04436224 - Hydromorphone for ICU-analgesia in Patients With Non-mechanical Ventilation Phase 4
Not yet recruiting NCT04548323 - Hypoalgesic Effects of Walking and Running Imagined
Completed NCT06054945 - Clinical Impact of IPACK Block Addition to Suprainguinal Fascia Iliaca Block
Completed NCT04394481 - Extension of Analgesia by Combined Injection of Dexamethasone and Dexmedetomidine After Arthroscopic Shoulder Surgery Phase 4
Completed NCT04690647 - The Efficacy of Suprainguinal Fascia Iliaca Compartment Block for Analgesia After Elective Total Hip Replacement. N/A
Completed NCT05034601 - ESPB vs TPVB for Postoperative Analgesia After the Nuss Procedure N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Recruiting NCT05454202 - Assessment of the Interest of ANI in the Non-communicating Patient in Palliative Care
Recruiting NCT04554186 - Serratus Anterior Plane Block Versus Thoracic Paravertebral Block. N/A
Suspended NCT04860635 - Safety of F14 Following Total Knee Replacement Phase 2/Phase 3
Not yet recruiting NCT06393777 - Effectiveness of Pre-administered Natural Sweet-tasting Solution (Honey) for Decreasing Pain of Needle Insertion N/A
Not yet recruiting NCT04519463 - The Effect of Local Anesthesia With Lidocaine During Insertion and Removal of Nasal Packing Early Phase 1
Completed NCT02916342 - Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks Phase 4
Not yet recruiting NCT02549118 - Tenoxicam for Intrapartum Analgesia Phase 2
Completed NCT03206554 - Local Infiltration Analgesia in Total Knee Arthroplasty Phase 2
Not yet recruiting NCT02190760 - Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block. N/A
Completed NCT01789606 - Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet Phase 3
Completed NCT01299584 - ULTIVA Post Marketing Surveillance N/A